What is the antibiotic of choice for infected scrofula (tuberculous cervical lymphadenitis)?

Antibiotic Treatment for Infected Scrofula (Tuberculous Cervical Lymphadenitis)

For drug-susceptible tuberculous cervical lymphadenitis (scrofula), treat with a 6-month regimen of rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months, followed by rifampicin and isoniazid for 4 months (2HRZE/4HR). 1

Treatment Approach

First-Line Therapy for Drug-Susceptible Disease

The standard regimen consists of:

Initial Phase (2 months):

• Rifampicin (R): 600 mg daily (or 450 mg if <50 kg)
• Isoniazid (H): 300 mg daily
• Pyrazinamide (Z): 2.0 g daily (or 1.5 g if <50 kg)
• Ethambutol (E): 15 mg/kg daily

Continuation Phase (4 months):

• Rifampicin: 600 mg daily
• Isoniazid: 300 mg daily

1, 2

This 6-month regimen is highly effective for peripheral lymph node tuberculosis, with cure rates approaching 100% when combined with appropriate surgical management 1, 3. The British Thoracic Society guidelines specifically confirmed that the 6-month regimen is as effective as 9-month regimens for tuberculous lymphadenitis 1.

Role of Surgery

Surgical excision is the primary treatment for NTM (nontuberculous mycobacterial) cervical lymphadenitis with >90% cure rate, but for tuberculous lymphadenitis, medical therapy is first-line. 4 However, surgical excision should be considered for:

• Extensive lymphadenopathy not responding to medical therapy
• Fluctuant nodes at risk of spontaneous drainage
• Persistent disease after adequate medical treatment (though residual nodes may persist without indicating treatment failure)

4, 3, 5, 6

Important caveat: Incision and drainage should be avoided as it is associated with prolonged wound discharge, fistula formation, and scarring 7, 8. If drainage is necessary, aspiration is preferred over incision and drainage.

Diagnostic Considerations Before Treatment

Before initiating therapy, confirm the diagnosis through:

• Fine-needle aspiration (FNA) with acid-fast bacilli smear - this is the most reliable diagnostic method, positive in the majority of cases 5
• Culture for mycobacterial species to distinguish M. tuberculosis from nontuberculous mycobacteria (NTM)
• Drug susceptibility testing to guide therapy
• PPD/tuberculin skin test (positive in approximately 79% of cases) 6
• Chest X-ray to exclude pulmonary involvement (abnormal in only 12-23% of cases) 9, 6

This distinction is critical because NTM cervical lymphadenitis is treated primarily with surgical excision rather than standard anti-TB chemotherapy 4.

Special Situations

If Pyrazinamide Cannot Be Used

Extend treatment duration to 9 months with rifampicin, isoniazid, and ethambutol for the initial 2 months, followed by rifampicin and isoniazid for 7 months 1.

Drug-Resistant Disease

For confirmed or suspected drug-resistant tuberculous lymphadenitis, treatment must be individualized based on drug susceptibility patterns:

• Isoniazid-resistant TB: Add a fluoroquinolone (levofloxacin or moxifloxacin) to a 6-month regimen of rifampin, ethambutol, and pyrazinamide 10
• MDR-TB: Requires longer regimens (18-24 months) with at least 4-5 effective drugs including bedaquiline, fluoroquinolones, and linezolid from WHO Group A agents 11

All drug-resistant cases should be discussed with TB experts or a TB consilium 11.

Monitoring and Follow-Up

• Daily dosing is strongly recommended over intermittent regimens 2
• Monitor for paradoxical reactions - lymph nodes may enlarge or new nodes may appear during treatment without indicating treatment failure 7
• Persistence of lymphadenopathy after treatment completion does not necessarily indicate relapse 7, 6
• Follow patients for 6 months post-treatment to detect relapse 12

Common Pitfalls

1. Misdiagnosing NTM as M. tuberculosis - NTM requires surgical excision, not prolonged chemotherapy 4
2. Performing incision and drainage - this leads to fistula formation and scarring; use aspiration if drainage needed 7, 8
3. Stopping treatment prematurely when nodes persist - residual lymphadenopathy is common and does not indicate treatment failure 7
4. Omitting ethambutol in the initial phase - the fourth drug is essential unless drug susceptibility is confirmed and resistance risk is very low 1